Observational Study
Copyright ©The Author(s) 2019.
World J Gastroenterol. Oct 28, 2019; 25(40): 6145-6157
Published online Oct 28, 2019. doi: 10.3748/wjg.v25.i40.6145
Table 1 Demographics of incident inflammatory bowel disease patients categorised by ethnicity
White European (n = 205)Indian(n = 68)Pakistani (n = 24)Other (n = 37)
Male sex, n (%)109 (53.2)42 (61.8)16 (66.7)25 (83.3)
Median age, yr (IQR range)
CD35 (25-54)32 (29-35)29 (23-44)19 (16-27)
UC40 (28-59)38 (29-50)29 (23-37)34 (25-45)
Median time from symptom onset to diagnosis, mo (IQR)
CD2.9 (0.9-8.5)3.0 (2.0-6.0)3.5 (2.0-5.3)3 (2.0-3.2)
UC2.3 (1.0-6.0)2.5 (0.98-4.0)2.7 (2.0-6.2)2.5 (1.7-3.4)
Smoking history, n (%)
CD
Never15 (22.0)3 (33.3)2 (40)3 (60)
Ex-smoker35 (51.4)3 (33.3)1 (20)1 (20)
Current18 (26.4)3 (33.3)2 (40)1 (20)
UC
Never35c (38.0)28a (75.7)7b (77.8)17a (85.0)
Ex-smoker35 (38.0)7 (19.0)1 (11.1)2 (10.5)
Current22 (24.0)2 (5.4)1 (11.1)1 (5.3)
Born in the United Kingdom (%)91.285.266.689.9
Family history of IBD, n (%)9 (5.7)4 (6.6)2 (11.1)1 (3.3)
Table 2 Medical and surgical treatment within 3 mo of diagnosis by ethnic group
White European, n (%)Indian, n (%)Pakistani, n (%)Other, n (%)Total, n (%)
UC
None5 (4.6)3 (6.4)1 (7.7)2 (9.5)11 (5.8)
5-ASA88 (81.5)42 (89.4)12 (92.3)12 (57.1)154 (81.4)
Steroids36 (33.3)16 (34.0)2 (15.4)4 (19.0)58 (30.7)
IM00000
Biologics7 (6.5)003 (14.3)10 (5.2)
Ciclosporin2 (1.9)0002 (1.0)
Surgery2 (1.9)002 (9.5)4 (2.1)
CD
None7 (8.5)2 (16.7)009
5-ASA31 (37.8)6 (50.0)2 (22.2)2 (28.6)43
Steroids34 (41.5)6 (50.0)6 (66.7)4 (57.1)50
IM19 (23.2)2 (16.7)4 (44.4)3 (42.9)28
Biologics12 (14.6)01 (11.1)1 (14.3)14
Other1 (1.2)0001
Surgery3 (3.7)0003